NASDAQ:AXDXAccelerate Diagnostics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Accelerate Diagnostics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.68 +0.77 (+9.73 %) (As of 04/9/2020 01:05 AM ET) Add Compare Share Today's Range$7.92Now: $8.68▼$8.9450-Day Range$4.62MA: $10.44▼$16.3852-Week Range$4.53Now: $8.68▼$24.00Volume538,259 shsAverage Volume358,111 shsMarket Capitalization$493.15 millionP/E RatioN/ADividend YieldN/ABeta2.97 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.Read More Beat the Market (BTM) Rank™ 3.1 Analyst's Opinion Consensus RatingAccelerate Diagnostics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.33, Accelerate Diagnostics has a potential upside of 111.2% from its current price of $8.68.Amount of Analyst CoverageAccelerate Diagnostics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesAccelerate Diagnostics has received 336 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAccelerate Diagnostics has received 296 “underperform” votes. (Add your “underperform” vote.)Community SentimentAccelerate Diagnostics has received 53.16% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Accelerate Diagnostics and other stocks. Vote “Outperform” if you believe AXDX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AXDX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAccelerate Diagnostics does not currently pay a dividend.Dividend GrowthAccelerate Diagnostics does not have a long track record of dividend growth. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Accelerate Diagnostics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,716,403.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders47.60% of the stock of Accelerate Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.23% of the stock of Accelerate Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Accelerate Diagnostics are expected to decrease by -39.47% in the coming year, from ($1.52) to ($0.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Accelerate Diagnostics is -5.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Accelerate Diagnostics is -5.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.1Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.17 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXDX Previous Symbol CUSIPN/A CIK727207 Webhttp://acceleratediagnostics.com/ Phone520-365-3100Debt Debt-to-Equity Ratio12.81 Current Ratio14.93 Quick Ratio13.94Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$9.30 million Price / Sales53.03 Cash FlowN/A Price / Cash FlowN/A Book Value($0.14) per share Price / Book-62.00Profitability EPS (Most Recent Fiscal Year)($1.55) Net Income$-84,310,000.00 Net Margins-903.51% Return on Equity-469.38% Return on Assets-55.03%Miscellaneous Employees287 Outstanding Shares56,814,000Market Cap$493.15 million Next Earnings Date5/14/2020 (Estimated) OptionableOptionable Receive AXDX News and Ratings via Email Sign-up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:AXDX Rates by TradingView Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions How has Accelerate Diagnostics' stock been impacted by COVID-19 (Coronavirus)? Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AXDX stock has decreased by 18.2% and is now trading at $8.68. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Accelerate Diagnostics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Accelerate Diagnostics. When is Accelerate Diagnostics' next earnings date? Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Accelerate Diagnostics. How were Accelerate Diagnostics' earnings last quarter? Accelerate Diagnostics Inc (NASDAQ:AXDX) posted its quarterly earnings data on Thursday, February, 27th. The medical research company reported ($0.39) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.04. The medical research company earned $3.50 million during the quarter, compared to the consensus estimate of $3.53 million. Accelerate Diagnostics had a negative net margin of 903.51% and a negative return on equity of 469.38%. View Accelerate Diagnostics' earnings history. What guidance has Accelerate Diagnostics issued on next quarter's earnings? Accelerate Diagnostics updated its FY 2020 After-Hours earnings guidance on Wednesday, January, 15th. The company provided EPS guidance of for the period. The company issued revenue guidance of $16-18 million, compared to the consensus revenue estimate of $27.93 million. What price target have analysts set for AXDX? 4 equities research analysts have issued twelve-month target prices for Accelerate Diagnostics' stock. Their forecasts range from $16.00 to $20.00. On average, they anticipate Accelerate Diagnostics' share price to reach $18.33 in the next year. This suggests a possible upside of 111.2% from the stock's current price. View analysts' price targets for Accelerate Diagnostics. What are Wall Street analysts saying about Accelerate Diagnostics stock? Here are some recent quotes from research analysts about Accelerate Diagnostics stock: 1. According to Zacks Investment Research, "Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, a rapid diagnostic platform for diagnosis in life-threatening bacterial infections and OptiChem(R) surface coatings for use in micro arraying components. Accelerate Diagnostics Inc., formerly known as Accelr8 Technology Corp., is based in Denver, Colorado. " (2/26/2020) 2. BTIG Research analysts commented, "Neutral AXDX reported Q1 revenue of $1.75M, short of consensus’ $1.9M forecast. Revenue was down sequentially by 4%. Although we had expected a revenue stepdown given the typical cadence of placements-to- conversions, the magnitude of the decline was less than we expected. In Q1, the company added 75 commercially contracted placements vs. 133 in 4Q18; to clarify, commercial placements refer to customers that have agreed to install and run tests (may or may not be active users). The company still sees a 4-9 month lag before instruments become active. On expectations for 2019, mgmt continues to target 300-400 placements as a full transition to the rental model and more comprehensive body of positive studies may drive up volumes." (5/12/2019) Has Accelerate Diagnostics been receiving favorable news coverage? Press coverage about AXDX stock has been trending very negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Accelerate Diagnostics earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutAccelerate Diagnostics. Who are some of Accelerate Diagnostics' key competitors? Some companies that are related to Accelerate Diagnostics include Quanterix (QTRX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), Arrayit (ARYC), HTG Molecular Diagnostics (HTGM), Scientific Industries (SCND), Aethlon Medical (AEMD), BioNano Genomics (BNGO), Precipio (PRPO), Pressure Biosciences (PBIO) and PositiveID (PSID). What other stocks do shareholders of Accelerate Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), BIOLASE (BIOL), Gilead Sciences (GILD), Alibaba Group (BABA), ABIOMED (ABMD), AT&T (T) and Vuzix (VUZI). Who are Accelerate Diagnostics' key executives? Accelerate Diagnostics' management team includes the following people: Mr. Lawrence Mehren, Pres, CEO, Director and Interim Head of Europe, Middle East & Africa (Age 53)Mr. Steve Reichling, Chief Financial Officer (Age 41)Mr. Ron Price, Sr. VP & Head of Commercial Operations - Americas (Age 55)Mr. Kurt Reinhardt, Head of OperationsDr. Romney M. Humphries, Chief Scientific Officer (Age 38) What is Accelerate Diagnostics' stock symbol? Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX." How do I buy shares of Accelerate Diagnostics? Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Accelerate Diagnostics' stock price today? One share of AXDX stock can currently be purchased for approximately $8.68. How big of a company is Accelerate Diagnostics? Accelerate Diagnostics has a market capitalization of $493.15 million and generates $9.30 million in revenue each year. The medical research company earns $-84,310,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. Accelerate Diagnostics employs 287 workers across the globe. View additional information about Accelerate Diagnostics. What is Accelerate Diagnostics' official website? The official website for Accelerate Diagnostics is http://acceleratediagnostics.com/. How can I contact Accelerate Diagnostics? Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected] This page was last updated on 4/9/2020 by MarketBeat.com StaffFeatured Article: What is the QQQ ETF?
